Ovarian cancer incidence in the United States, 1992–1999

Clinical and Pathologic Features of Patients with Rare Ovarian Tumors: Multi-Center Review of 167 Patients by the Anatolian Society of Medical Oncology

“…They have different biological behaviors with a variety of histopathological subtypes; in addition, they have curative potential with different treatment approaches compared with much more commonly encountered epithelian ovarian cancers (Quirk and Natarajan, 2005;Young, 2005;Ayhan et al, 2009;Koulouris and Penson, 2009;Colombo et al, 2012;Penson, 2013;Takeuchi et al, 2013). The cure rates of early stage GCTs approach 100%, and even in the advanced stage of the disease, surgery and the BEP regimen result in cure rates of approximately 75% (Gershenson, 2007;Parkinson et al, 2011;Matei et al, 2013).…”

Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation

“…Epithelial ovarian cancer represents 90 -95% of all ovarian tumours (Auersperg et al, 2001;Quirk and Natarajan, 2005), which is detected in 60.6% cases in advanced stages of disease due to unspecific or absent symptoms in early stages. Although tremendous efforts have been undertaken to improve the therapeutic outcome, ovarian cancer still remains the most lethal malignoma among gynaecological tumours of women in the western world, given that only 35% of ovarian cancer patients show a 5-year survival (Legge et al, 2005).…”

Pregnancy with Ovarian Dysgerminoma : An Unusual Diagnosis

“…22 Similarly, Antoshechkina ET reported stage 1 tumor in nearly 70% of cases in their study of 80 cases. They also commented that stage and size of neoplasm had the highest prognostic value.…”